



ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20230801045

Date: August 01, 2023

To, BSE Limited , Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai -400001, India SCRIP CODE: 543275	To, National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex Bandra (East), Mumbai 400051, India SYMBOL: ANURAS
--	---

Dear Sir/Madam,

Subject: Press Release Intimation

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Press Release to be issued by the Company today i.e. Tuesday, August 01, 2023 regarding the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2023, approved by the Board of Directors of the Company.

This Press Release will also be available on the website of the Company www.anupamrasayan.com.

We request you to kindly take note of the same.

Thanking You,

Yours faithfully,

For Anupam Rasayan India Limited

Anand Desai
Managing Director
DIN: 00038442

Encl.: As above

PRESS RELEASE

For Immediate dissemination



ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited Reports Q1FY24 Results

Q1FY24 Total Revenue of ₹3,988 Mn; growth of 19% YoY
Q1FY24 EBITDA at ₹1,138 Mn; growth of 28% YoY; Q1FY24 EBITDA Margin at 29%

Surat, August 1, 2023: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India's leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended June 30, 2023.

Consolidated Financial Highlights for Quarter ended June 30, 2023:

- Total Revenue at ₹3,988 million in Q1FY24 as compared to ₹3,343 million in Q1FY23 – growth of 19% Y-o-Y.
- EBITDA (incl. other revenue) at ₹1,138 million in Q1FY24 as compared to ₹892 million in Q1FY23 – growth of 28% Y-o-Y.
- Profit After Tax at ₹523 million in Q1FY24 as compared to ₹420 million in Q1FY23 - growth of 25% Y-o-Y.

Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented, "I am delighted at the consistent growth momentum of the Company against a challenging industry backdrop. Our consolidated revenue witnessed robust 19% Y-o-Y growth at Rs 3,988 Mn. While the falling prices of commodity agrochemicals are putting pressure on margins for the industry, our customised products and robust business model helped us deliver strong EBITDA margins of 29% in Q1 FY24.

During the quarter, Anupam Rasayan signed an MoU with 3xper Innoventure Ltd., for the supply of targeted and identified new-age pharma molecules using continuous process. The Company has also signed Letters of Intent (LOIs) worth Rs 40,660 Mn with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOIs reinforce the growing confidence of global MNCs in our technical capabilities and think of us as the trusted partner of choice for high-end customised molecules. These LOIs improves our revenue visibility in the coming years.

Our order book remains strong despite a challenging external environment, giving us the confidence to deliver robust growth in FY24 while maintaining margins."

About Anupam Rasayan India Ltd. (ARIL):

Anupam Rasayan India Ltd (ARIL) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the speciality chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Specialty Pigment and Dyes, and Polymer Additives. The Company caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 73 domestic and international customers, including 29 multinational companies. The Company operates via its six manufacturing facilities in Gujarat, India, with four facilities located at Sachin, Surat and two located at Jhaghadia, Bharuch with an aggregate installed capacity of about 27,000 MT, as of June 30, 2023. ARIL offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers. The Company is focussed on developing in-house innovative processes for manufacturing products requiring complex chemistries and achieving cost optimization.

For further details, please get in touch with:

IR Contact: Ernst & Young LLP

Rahul Thakur / Advait Bhadekar

Email: rahul.thakur@in.ey.com

advait.bhadekar@in.ey.com

PR Contact

Sanchi Yadav

Email: sanchi.yadav@adfactorspr.com

Phone: + 91 98336 40764